Liver metastasis from breast cancer
Conditions
Interventions
Drug-elunting beads transcatheter arterial chemoembolization group:No
Sponsors
The Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
Female
Age
17 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Female patients aged 18-70 years; 2. Patients with previous pathological diagnosis of breast cancer were diagnosed with liver metastases by surgery or clinical diagnosis; 3. Patients refuse surgery or contraindications, refuse radiofrequency ablation, radiotherapy and other treatment schemes, and are willing to accept interventional therapy; 4. ECOG general condition score: 0-2 points; 5. The CT/MRI image of the patient's liver must contain a measurable lesion >= 10 mm, and the above examination must be completed within 15 days before the treatment; 6. Hematological examination 7 days before enrollment showed normal bone marrow function, liver and kidney function, i.e. hemoglobin >= 90 g/L; Leukocyte count >= 4.0 x 10^9/L, neutrophil count >= 2.0 x 10^9/L, platelet count >= 100 x 10^9/L, total bilirubin(TBIL) <= 1.0 upper normal limit, creatinine(CR) <= 1.0 upper normal limit, alanine aminotransferase and aspartate aminotransferase <= 2.5 upper normal limit, alkaline phosphatase <= 5.0 upper normal limit; 7. Routine ECG examination showed that the ECG function was normal and there was no history of heart failure; 8. Patients had good treatment compliance and were willing to accept long-term follow-up; 9. Sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Poor bone marrow function and liver and kidney dysfunction may cause chemotherapy intolerance; 2. There are relative contraindications to interventional therapy: such as poor child rating, cachexia, etc; 3. Currently participating in other clinical trials; 4. Relevant medical conditions of clinical significance and uncontrolled, including but not limited to: uncontrollable infection, symptomatic congestive heart failure, unstable angina pectoris or arrhythmia, mental illness/social conditions, which will limit compliance with the study requirements; For any medical condition, the researchers believe that the subject is at an unacceptably high risk.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR);T Cell; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival (OS);Profression-free survival (PFS); | — |
Countries
China
Contacts
Public ContactWang Song
The Affiliated Hospital of Qingdao University
Outcome results
None listed